Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients